Search

Author/Creator Rotevatn, S

2. Informing patients about potential adverse drug reactions after percutaneous coronary intervention reduces the occurrence of self-reported adverse drug reactions. (3rd October 2022)

Authors:
Pettersen, T; Schjott, J; Allore, H; Bendz, B; Borregaard, B; Fridlund, B; Hadjistavropoulos, H D; Larsen, A I; Nordrehaug, J E; Rasmussen, T B; Rotevatn, S; Valaker, I; Wentzel-Larsen, T; Norekval, T M
Journal:
European heart journal
Issue:
Volume 43(2022)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Sex, age, and cohabitation status: is it associated with perceived need of follow-up after percutaneous coronary intervention?. (3rd October 2022)

Authors:
Hjertvikrem, N; Instenes, I; Borregaard, B; Brors, G; Falun, N; Helmark, C; Palm, P; Pettersen, T R; Rotevatn, S; MacNeil Vroomen, J L; Zwisler, A D; Norekval, T M
Journal:
European heart journal
Issue:
Volume 43(2022)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Time from ECG Diagnosis to sheath insertion is a strong predictor for mortality in patients with ST elevation myocardial infarction admitted for primary percutaneous coronary intervention. (25th November 2020)

Authors:
Larsen, A.I; Loland, K; Hovland, S; Bleie, O; Trovik, T; Hegbom, K; Larsen, T; Fossum, E; Eek, C; Moer, R; Juliebo, V; Uchto, M; Rotevatn, S
Journal:
European heart journal
Issue:
Volume 41:(2020)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗